IGFBPL1 mediates its effects by binding to IGF1R on neurons, activating ERK signaling, and increasing TRPV1 channel responsiveness to heat and capsaicin; blocking IGF1R or ERK signaling reduced pain, indicating a dual neuronal and inflammatory mechanism.

IGFBPL1 influences immune responses by promoting macrophage infiltration and inflammatory cytokine production (TNF-α, IL-1β, IL-6) in the dorsal root ganglion; eliminating macrophages nullified IGFBPL1’s pain-inducing effect, suggesting an inflammatory axis in chronification.

IGFBPL1 enhances TRPV1 channel responsiveness to noxious heat and capsaicin, contributing to heightened pain signaling; it also promotes macrophage infiltration and pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) in the DRG.

The research proposes a potential therapeutic strategy targeting the dorsal root ganglion to treat neuropathic pain without opioids, though the study was conducted mainly in male mice and needs validation in female animals, other pain models, and human tissue.

The findings suggest a potential therapeutic strategy targeting the DRG to treat neuropathic pain without opioids, with future validation planned in female mice and other pain models including diabetes- and chemotherapy-induced neuropathy.

Administration of IGFBPL1 worsens pain hypersensitivity in nerve-injured mice, while it does not affect pain in uninjured mice, indicating a injury-specific role in amplifying pain.

The pain amplification occurs specifically under injured conditions, as normal mice did not show pain changes upon IGFBPL1 administration, suggesting a favorable safety profile in non-injured states.

A research team at Gwangju Institute of Science and Technology identified IGFBPL1 as a key protein that rises in sensory neurons after peripheral nerve injury and drives the onset and persistence of neuropathic pain.

A team from the Gwangju Institute of Science and Technology (GIST) led by Professor Jung Eui-heon identified IGFBPL1 as a key regulator that amplifies and sustains chronic neuropathic pain after peripheral nerve injury.

The study, published in the Journal of Neuroinflammation, emphasizes the broader impact on the neuropathic pain treatment landscape by offering a new molecular target beyond traditional antidepressants and anticonvulsants.

Suppression of IGFBPL1 via siRNA in the dorsal root ganglion reduces mechanical and thermal pain hypersensitivity, with effects lasting up to six weeks in a partial peripheral nerve injury model; neutralizing antibodies provide transient relief.

Experimental suppression of IGFBPL1 using siRNA in the dorsal root ganglion alleviated pain hypersensitivity, with relief lasting up to six weeks in a partial nerve injury model; neutralizing antibodies also produced temporary relief when administered four weeks post-injury; adding IGFBPL1 worsened pain in injured mice.